on 20 Jun 2023
Last Applicant/ Owned by
CY-2003 Nicosia
CY
Serial Number
79324818 filed on 25th May 2021
Registration Number
7082461 registered on 20th Jun 2023
Correspondent Address
Julianne AbelmanWomble Bond ickinson (US) LLP
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
Research and development in the field of blood, blood products being comprised of a synergistic cell population of stem cells including angiogenic cell precursors, and blood testing; scientific research services in the field of blood and stem cells Services in the medical field, namely, medical services performed in a laboratory for medical research companies, the foregoing consisting of extractiRead More
Services in the medical field, namely, medical services performed in a laboratory for medical research companies, the foregoing consisting of extracting, processing, culturing, testing, injecting or administering under medical supervision the products derived from blood and blood components being a novel human cell population; services in the medical field, namely, medical services performed in a laboratory for medical research companies, the foregoing consisting of selecting, processing, manipulating, purging and storing stem cells from blood and adding regenerative cells to the body
Research and development in the field of blood, blood products being comprised of a synergistic cell population of stem cells including angiogenic cell precursors, and blood testing; scientific research services in the field of blood and stem cells
Stem cell preparations used for the treatment of peripheral neuropathy, peripheral vascular disease, critical limb ischemia, wound care, end-stage heart diseases, angina pectoris, ischemic and dilated cardiomyopathy, COP, idiopathic pulmonary hypertension and other diseases of ischemia; biomedical autologous preparations in the nature of hematopoietic stem cells that include a synergetic cell population of angiogenic cell precursors used for the treatment of minor health disorders to prevent them from becoming severe health disorders, and to treat severe health disorders on an ongoing basis to slow, eliminate, or reverse their progress
Stem cell preparations used for research of peripheral neuropathy, peripheral vascular disease, critical limb ischemia, wound care, end-stage heart diseases, angina pectoris, ischemic and dilated cardiomyopathy, COP, idiopathic pulmonary hypertension and other diseases of ischemia; biomedical autologous preparations in the nature of hematopoietic stem cells that include a synergetic cell population of angiogenic cell precursors used for research, other experiments of minor health disorders to prevent them from becoming severe health disorders
No 79324818
No Service Mark
No 115889.130.9
No
No
No
No
Yes
Yes
No
No
| Status Date | Action Taken |
|---|---|
| 26th Apr 2024 | TEAS CHANGE O CORRESPONENCE RECEIVE |
| 26th Apr 2024 | TEAS WITHRAWAL O ATTORNEY RECEIVE-IRM RETAINS |
| 26th Apr 2024 | ATTORNEY/OM.REP.REVOKE AN/OR APPOINTE |
| 26th Apr 2024 | TEAS REVOKE/APP/CHANGE AR O ATTY/OM REP RECEIVE |
| 10th Oct 2023 | INAL ECISION TRANSACTION PROCESSE BY IB |
| 21st Sep 2023 | INAL ISPOSITION PROCESSE |
| 21st Sep 2023 | INAL ISPOSITION NOTICE SENT TO IB |
| 20th Sep 2023 | INAL ISPOSITION NOTICE CREATE, TO BE SENT TO IB |
| 20th Jun 2023 | REGISTERE-PRINCIPAL REGISTER |
| 20th Jun 2023 | NOTICE O REGISTRATION CONIRMATION EMAILE |
